Short communication · 24 Dec 2024
Short communicationPublished 17 Aug 2021
Brief Overview on "Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture"
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The COVID-19 pandemic remains a pressing global challenge. Worldwide mortality attributable to COVID-19 now exceeds 4 million deaths. There is an urgent need for developing novel therapeutics to treat SARS-CoV-2. Our recent study showed brilacidin, a synthetic small molecule with peptide-like properties, potently inhibits SARS-CoV-2 in cell culture. Additionally, brilacidin exhibited in vitro inhibition in combination with remdesivir, the only FDA-approved drug for treatment of COVID-19. Brilacidin is currently undergoing Phase 2 clinical testing for treatment of moderate-to-severe COVID-19 in hospitalized patients.
Subjects
MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Archives of Clinical Microbiology.
Short communication · 24 Dec 2024
Exploring the Frontiers of Microbial Genomics: Unravelling the Secrets of Microbial Diversity
Short communication · 24 Dec 2024
Staphylococcus aureus: A Microbial Mastermind
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalArchives of Clinical Microbiology
- SubjectMicrobiology
- BylineArticles whose byline prints “Warren K. Weston”
- BylineArticles whose byline prints “Jane A. Harness”
- BylineArticles whose byline prints “Aarthi Narayanan”
